[Treatment of toxoplasmosis].
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002981:Clindamycin / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007933:Leucomycins / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D011739:Pyrimethamine / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013424:Sulfanilamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D013754:Tetracyclines / Q000627:therapeutic use; D014123:Toxoplasmosis / Q000188:drug therapy*; D014124:Toxoplasmosis, Animal / Q000188:drug therapy; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000981:Antiprotozoal Agents; D004338:Drug Combinations; D007933:Leucomycins; D013424:Sulfanilamides; D013450:Sulfones; D013754:Tetracyclines; D002981:Clindamycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole; D012293:Rifampin; D011739:Pyrimethamine
La terapia della toxoplasmosi.